Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures (0.22%), Hang Seng Futures +0.12%, ASX SPI 200 (0.46%), S&P Futures (0.14%)

Dec 29 ,2025

  • Synopsis:

    • Asia equities poised to open mostly lower Monday. Futures in Japan and Australia were softer, Hong Kong marginally higher. Golden Dragon China index fell 1.54%. US futures stabilized following a weak Friday session in uneventful trading. Tech leads were negative; Mag 7 declined, SOX fell notably. Treasuries were mixed with the curve steepening. Dollar index was down 0.1%. Gold finished down 0.8%, but off worst levels. Bitcoin futures down 1.3%. WTI crude settled up 1.4%.

    • Soft finish to the week was put down to general profit-taking from earlier strength and year-end rebalancing through holiday-induced light volumes. Little immediate conviction in the narrative as markets digest 2024 performance and look ahead to 2025 themes (US debt limit notwithstanding). Ongoing US economic resilience, stubborn inflation, Trump policy uncertainties extrapolating into the new year. Relatively positive market tone contrasting with cautious projections around 2023-end. AI boom contributed to upside this year. Financials seen among sectors standing to benefit from Trump policies in 2025.

    • Current Asia themes similarly carrying over into the new year. Trump tariffs set to be pivotal as press reports discuss estimates of broader regional impact. Markets still awaiting China fiscal stimulus size and details, though economists do not expect an announcement that markets were hoping for. Some expectations that policy support will be expanded depending on how far Trump follows through on tariff hikes. Main event in Asia macro calendar this week set to be China PMIs with official gauges (Tue) expected to remain steady. South Korea industrial production unexpectedly declined, leading other month-end releases including CPI (Tue) and customs trade (Wed).

  • Pre-open Company News:

    • 542812.IN -- Gujarat Fluorochemicals announces temporary disruption of operations at CMS-1 plant of the company situated at Dahej, Gujarat

    • TLX.AU -- Telix Pharmaceuticals submits BLA to FDA for TLX250-CDx (Zircaix, 89Zr-girentuximab) kidney cancer imaging

    • Estimated weekend box office revenues in US, Canada $162.8M, +44.2% y/y - Box Office Mojo

    • 600276.CH -- Follow-up: Jiangsu Hengrui Pharmaceuticals grants IDEAYA Biosciences exclusive license for SHR-4849 outside greater China

    • 2577.HK -- InnoScience (Suzhou) Technology's 45.4M-share Hong Kong IPO priced at HK$30.86/share through CICC, CMBI

    • 5225.MK -- IHH Healthcare resumed buy at Maybank Investment Bank

    • 600276.CH -- Jiangsu Hengrui Pharmaceuticals grants paid license of SHR-4849 to IDEAYA Biosciences

    • 6594.JP -- Street Takeaways - Nidec's tender offer for Makino Milling

    • 2685.JP -- Street Takeaways - Adastria Q3 Earnings

  • On Deck:

    • No releases found for today

  • Market Data:

    • Gold (Feb 25): +$6.20 or +0.24% to $2638.10

    • WTI Crude (Feb 25): ($0.22) or (0.31%) to $70.38

    • $-¥: +0.02 or +0.01% to 157.8870

    • $-KRW: (0.75) or (0.05%) to 1472.8000

    • A$-$: +0.00 or +0.14% to 0.6228

    • $-INR: +0.01 or +0.01% to 85.3880

    • $-CNY: (0.00) or (0.02%) to 7.2975

  • If you would like to receive the Asian Market Preview daily, please search for Asia Pre-Market Updates in Alert Manager.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE